Drug Trial Radar · NCT01458119
Open-Label Phase 3 Long-Term Safety Study of Migalastat
Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
85
Actual
Start
Oct 14, 2011
Primary completion
Feb 17, 2016
Study completion Feb 17, 2016
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a long-term, open-label study of migalastat (123 milligrams \[mg\] of migalastat \[equivalent to 150 mg of migalastat hydrochloride\]) (migalastat) in participants with Fabry disease who completed treatment in a previous monotherapy trial with migalastat.
Conditions
- Fabry Disease
Interventions
migalastat hydrochlorideDrug
Oral capsule QOD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.
Locations
25 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Kansas City, Kansas
Site not named
Boston, Massachusetts
Site not named
Grand Rapids, Michigan
Site not named
New York, New York
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Dallas, Texas
Site not named
Fairfax, Virginia
Site not named
Seattle, Washington
Site not named
Pilar, Argentina
Site not named
Adelaide, Australia
Site not named
Parkville, Australia
Site not named
Edegem, Belgium
Site not named
Porto Alegre, Brazil
Site not named
Montreal, Canada
Site not named
Copenhagen, Denmark
Site not named
Cairo, Egypt
Site not named
Garches, France
Site not named
Roma, Italy
Site not named
Barcelona, Spain
Site not named
Ankara, Turkey (Türkiye)
Site not named
London, United Kingdom
Site not named
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.